Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CMPS with free AI briefings, catalyst countdowns, and dilution alerts.

CMPS · COMPASS Pathways plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$444M Cash on Hand
29.2mo Cash Runway
12.3% Short Interest
$23.31 Analyst Target (16)
Follow CMPS by email Get an email when CMPS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CMPS, unsubscribe in one click. Privacy

📣 What CMPS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
COMP360 psilocybin PTSD - Post Traumatic Stress Disorder Phase 2/3 · NCT07570654 Recruiting
Tovecimig (CTX-009) Biliary Tract Cancer Phase 2/3 · NCT05506943 Active not recruiting
Psilocybine Treatment Resistant Depression Phase 3 · NCT05711940 Active not recruiting
Fluorouracil Colorectal Cancer Phase 2 · NCT07662031 Not yet recruiting
Anti-CD137 Agonistic Monoclonal Antibody CTX-471 Glioblastoma Phase 1/2 · NCT07392957 Recruiting
Irinotecan Colorectal Cancer Phase 2 · NCT07662031 Not yet recruiting
CTX-10726 Gastroesophageal Cancer (GC) Phase 1 · NCT07419841 Recruiting
Anti-PD-1/Anti-PD-L1 Bispecific Antibody… Non Small Cell Lung Cancer Phase 1 · NCT06150664 Recruiting

Also used in these trials (approved or third-party drugs, not CMPS's own candidates): Paclitaxel, Cisplatin, Durvalumab, Gemcitabine Hydrochloride, Leucovorin, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CMPS holds $444M in cash and short-term investments (as of Sep 30, 2026) and burns about $45.5M/quarter from operations, an estimated runway of 29.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 34 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CMPS files for a raise →

👥 Who Owns CMPS

Insiders 8.9% Institutions (286 holders) 69.3% Public and other holders 21.8%
HolderTypeShares% of sharesAs of
RTW Investments, LP Institution (13G, 5%+) 12,971,571 9.15% 2026-03-31
Deep Track Capital, Lp Institution (13F) 12,161,496 8.58% 2026-09-30
BIT Capital GmbH Institution (13G, 5%+) 8,148,280 5.75% 2026-09-30
Ekaterina Malievskaia
10% owner
Insider 6,307,970 4.45% 2024-10-24
George Jay Goldsmith
10% owner
Includes shares also reported by Ekaterina Malievskaia, counted once
Insider 6,307,970 4.45% 2024-10-24
Life Sciences N.V. ATAI
10% owner
Insider 5,785,774 4.08% 2025-10-27
Tang Capital Management, LLC Institution (13F) 5,200,000 3.67% 2026-09-30
ARK Investment Management, LLC Institution (13F) 4,905,613 3.46% 2026-09-30
Point72 Asset Management, L.P. Institution (13F) 4,737,706 3.34% 2026-09-30
Two Sigma Investments, LP Institution (13F) 4,279,191 3.02% 2026-09-30
Bank of America Corporation Institution (13F) 3,200,714 2.26% 2026-09-30
UBS Group AG Institution (13F) 3,119,254 2.20% 2026-09-30

Share count 141,710,353 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-03
filed 2026-08-05
Nath Kabir
Tax withholding (F) 5,962 $11.25 361,028
2026-05-27
filed 2026-05-29
McQuade Robert
Option award (A) 21,110 – –
2026-05-27
filed 2026-05-29
Tregoning Kathleen
Option award (A) 41,119 – –
2026-05-27
filed 2026-05-29
Karydas Daphne
Option award (A) 21,110 – –
2026-05-27
filed 2026-05-29
Gover Justin D.
Option award (A) 21,110 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full CMPS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMPS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.